Eagle Health Investments
Eagle Health Investments reported 22 stocks worth $582M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are ARGX (12.6%), GH (9.2%) and ICLR (7.7%). Compared with Q2 2026, the fund opened new positions in UTHR, ROIV and REPL, added to ARGX, ISRG and SRRK, trimmed ICLR, INSM and KYMR and sold out of BMRN, ILMN and RARE.
Latest filing: what Eagle Health Investments did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ARGX Argenx SE | $73.4M | 12.6% | 77K | +176 (+0%) | 8 of 8 | |
| 2 | ![]() GH Guardant Health Inc | $53.6M | 9.2% | 301K | No change | 6 of 8 | |
| 3 | ![]() ICLR Icon PLC | $45M | 7.7% | 265K | −43K (−14%) | 8 of 8 | |
| 4 | ![]() ISRG Intuitive Surgical Inc | $44.1M | 7.6% | 109K | +104K (+2373%) | 8 of 8 | |
| 5 | ![]() UTHR United Therapeutics Corp Del | $43.2M | 7.4% | 80K | New position | 2 of 8 | |
| 6 | ![]() INSM Insmed Inc | $40.9M | 7.0% | 359K | −25K (−7%) | 8 of 8 | |
| 7 | ![]() PTGX Protagonist Therapeutics Inc | $35M | 6.0% | 248K | No change | 4 of 8 | |
| 8 | ![]() ROIV Roivant Sciences Ltd | $32.2M | 5.5% | 879K | New position | 1 of 8 | |
| 9 | ![]() SRRK Scholar Rock Hldg Corp | $27.1M | 4.7% | 562K | +6,255 (+1%) | 6 of 8 | |
| 10 | ![]() ASND Ascendis Pharma A/s | $27M | 4.7% | 119K | +12K (+12%) | 2 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() BMRN Biomarin Pharmaceutical Inc | $35.7M | 625K |
![]() ILMN Illumina Inc | $33M | 187K |
![]() RARE Ultragenyx Pharmaceutical in | $29.5M | 884K |
![]() IONS Ionis Pharmaceuticals Inc | $15.4M | 195K |
![]() TEM Tempus AI Inc | $14.8M | 256K |
🔒 Free account: see all 9.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() GH Guardant Health Inc | Put | $26.8M | 150K | +150,300 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Eagle Health Investments 13F FAQ
What does Eagle Health Investments own?
Eagle Health Investments reported 22 stocks worth $582M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are ARGX (12.6%), GH (9.2%) and ICLR (7.7%). The table above lists every position in the filing (the top 10 without an account).
What did Eagle Health Investments buy and sell in Q3 2026?
Compared with Q2 2026: 4 new positions, 5 added to, 3 trimmed and 9 sold out. New positions include UTHR, ROIV and REPL. It sold all of BMRN, ILMN and RARE.
When will Eagle Health Investments file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Eagle Health Investments's portfolio worth?
The Q3 2026 filing reports $582M in US stocks ($609M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.


















